Lv1
10 积分 2025-03-20 加入
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
20小时前
待确认
Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma
2个月前
已完结
Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
2个月前
已完结
Cost-effectiveness of Pembrolizumab in advanced endometrial cancer: A systematic review
2个月前
已完结
Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial
4个月前
已完结
需要该文章的附件
1年前
已完结
皖公网安备34019202002308
